Name: characterize disease-related mutants of raf family kinases by using a set of practical and feasible methods
Uploaded: 2019-07-17T13:30:00
Description: Watch this Scientific Journal Video about Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods at JoVE.com

The authors would like to acknowledge the Hairy Cell Leukemia Fellowship for support of Yuan Jimin. This work was supported by Asia Fund Cancer Research (AFCR2017/2019-JH), Duke-NUS Khoo Bridge Funding Award (Duke-NUS-KBrFA/2018/0014), NCCRF bridging grant (NCCRF-YR2018-JUL-BG4), NCCRF pilot grant (NCCRF-YR2017-JUL-PG3), and SHF Academic Medicine Research Grant (AM/TP011/2018).

1. In Vitro Kinase Assay for Measuring the Catalytic Activity of RAF Mutants
<ol>
	<li>Construct vectors encoding RAF mutants (Figure 1A) with FLAG(DYKDDDDK) tag at C-terminus by using Gibson Assembly or traditional molecular cloning methods.
	<ol>
		<li>Introduce the FLAG tag and mutations into the RAF coding sequences by PCRs, and then insert whole sequences into pCDNA3.1(+) vector by using Gibson assembly or T4 DNA ligation and following the manufacture&#8217;s protocol...

<ol>
	<li>Chong, H., Vikis, H. G., Guan, K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mechanisms+of+regulating+the+Raf+kinase+family.">Mechanisms of regulating the Raf kinase family.</a> Cellular Signalling. 15 (5), 463-469 (2003).</li><li>Wellbrock, C., Karasarides, M., Marais, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+RAF+proteins+take+center+stage.">The RAF proteins take center stage.</a> Nature Reviews Molecular Cell Biology. 5 (11), 875-885 (2004).</li><li>Baccarini, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Second+nature:+biological+functions+of+the+Raf-1+"kinase".">Second nature: biological functions of the Raf-1 "kinase".</a> FEBS Letter. 579 (15), 3271-3277 (2005).</li><li>Lavioe, H., Therrien, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Regulation+of+RAF+protein+kinases+in+ERK+signaling.">Regulation of RAF protein kinases in ERK signaling.</a> Nature Reviews Molecular Cell Biology. 16 (5), 281-298 (2015).</li><li>Schreck, R., Rapp, U. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Raf+kinases:+oncogenesis+and+drug+discovery.">Raf kinases: oncogenesis and drug discovery.</a> International Journal of Cancer. 119 (10), 2261-2271 (2006).</li><li>Roberts, P. J., Der, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer.">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.</a> Oncogene. 26 (22), 3291-3310 (2007).</li><li>McCubrey, J. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Roles+of+the+Raf/MEK/ERK+pathway+in+cell+growth,+malignant+transformation+and+drug+resistance.">Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.</a> Biochemistry Biophysics Acta. 1773 (8), 1263-1284 (2007).</li><li>Schubbert, S., Shannon, K., Bollag, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hyperactive+Ras+in+developmental+disorders+and+cancer.">Hyperactive Ras in developmental disorders and cancer.</a> Nature Reviews Cancer. 7 (4), 295-308 (2007).</li><li>Davies, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mutations+of+the+BRAF+gene+in+human+cancer.">Mutations of the BRAF gene in human cancer.</a> Nature. 417 (6892), 949-954 (2002).</li><li>Garnett, M. J., Marais, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Guilty+as+charged:+B-RAF+is+a+human+oncogene.">Guilty as charged: B-RAF is a human oncogene.</a> Cancer Cell. 6 (4), 313-319 (2004).</li><li>Pandit, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Gain-of-function+RAF1+mutations+cause+Noonan+and+LEOPARD+syndromes+with+hypertrophic+cardiomyopathy.">Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.</a> Nature Genetics. 39 (8), 1007-1012 (2007).</li><li>Mason, C. S., Springer, C. J., Cooper, R. G., Superti-Furga, G., Marshall, C. J., Marais, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Serine+and+tyrosine+phosphorylations+cooperate+in+Raf-1,+but+not+B-Raf+activation.">Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.</a> EMBO Journal. 18 (8), 2137-2148 (1999).</li><li>Hu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Allosteric+activation+of+functionally+asymmetric+RAF+kinase+dimers.">Allosteric activation of functionally asymmetric RAF kinase dimers.</a> Cell. 154 (5), 1036-1046 (2013).</li><li>Desideri, E., Cavallo, A. L., Baccarini, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Alike+but+different:+RAF+paralogs+and+their+signaling+outputs.">Alike but different: RAF paralogs and their signaling outputs.</a> Cell. 161 (5), 967-970 (2015).</li><li>Yuan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+dimer-dependent+catalytic+activity+of+RAF+family+kinases+is+revealed+through+characterizing+their+oncogenic+mutants.">The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.</a> Oncogene. 37 (43), 5719-5734 (2018).</li><li>Wan, P. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF.">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.</a> Cell. 116 (6), 855-867 (2004).</li><li>Shaw, A. S., Kornev, A. P., Hu, J., Ahuja, L. G., Taylor, S. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Kinases+and+pseudokinases:+lessons+from+RAF.">Kinases and pseudokinases: lessons from RAF.</a> Molecular and Cellular Biology. 34 (9), 1538-1546 (2014).</li><li>Taylor, S. S., Shaw, A. S., Hu, J., Meharena, H. S., Kornev, A. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pseudokinases+from+a+structural+perspective.">Pseudokinases from a structural perspective.</a> Biochemistry Society Transactions. 41 (4), 981-986 (2013).</li><li>Rajakulendran, T., Sahmi, M., Lefran&#231;ois, M., Sicheri, F., Therrien, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+dimerization-dependent+mechanism+drives+RAF+catalytic+activation.">A dimerization-dependent mechanism drives RAF catalytic activation.</a> Nature. 461 (7263), 542-545 (2009).</li><li>Heidorn, S. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF.">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.</a> Cell. 140 (2), 209-221 (2010).</li><li>Yuan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Activating+mutations+in+MEK1+enhance+homodimerization+and+promote+tumorigenesis.">Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis.</a> Science Signaling. 11 (554), 6795 (2018).</li><li>Yuan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+AMPK+inhibitor+overcomes+the+paradoxical+effect+of+RAF+inhibitors+through+blocking+phospho-Ser-621+in+the+C+terminus+of+CRAF.">The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.</a> Journal of Biological Chemistry. 293 (37), 14276-14284 (2018).</li><li>Hu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Kinase+regulation+by+hydrophobic+spine+assembly+in+cancer.">Kinase regulation by hydrophobic spine assembly in cancer.</a> Molecular and Cellular Biology. 35 (1), 264-276 (2015).</li><li>Poulikakos, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RAF+inhibitor+resistance+is+mediated+by+dimerization+of+aberrantly+spliced+BRAF(V600E).">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).</a> Nature. 480 (7377), 387-390 (2011).</li><li>Hu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mutation+that+blocks+ATP+binding+creates+a+pseudokinase+stabilizing+the+scaffolding+function+of+kinase+suppressor+of+Ras,+CRAF+and+BRAF.">Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.</a> Proceedings of the National Academy of Sciences of the United States of America. 108 (15), 6067-6072 (2011).</li><li>Taylor, S. S., Kornev, A. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protein+kinases:+evolution+of+dynamic+regulatory+proteins.">Protein kinases: evolution of dynamic regulatory proteins.</a> Trends Biochemistry Sciences. 36 (2), 65-77 (2011).</li><li>Farrar, M. A., Alberol-Ila, J., Perlmutter, R. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Activation+of+the+Raf-1+kinase+cascade+by+coumermycin-induced+dimerization.">Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization.</a> Nature. 383 (6596), 178-181 (1996).</li><li>Luo, Z., Tzivion, G., Belshaw, P. J., Vavvas, D., Marshall, M., Avruch, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oligomerization+activates+c-Raf-1+through+a+Ras-dependent+mechanism.">Oligomerization activates c-Raf-1 through a Ras-dependent mechanism.</a> Nature. 383 (6596), 181-185 (1996).</li><li>Weber, C. K., Slupsky, J. R., Kalmes, H. A., Rapp, U. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Active+Ras+induces+heterodimerization+of+cRaf+and+BRaf.">Active Ras induces heterodimerization of cRaf and BRaf.</a> Cancer Research. 61 (9), 3595-3598 (2001).</li><li>Garnett, M. J., Rana, S., Paterson, H., Barford, D., Marais, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Wild-type+and+mutant+B-RAF+activate+C-RAF+through+distinct+mechanisms+involving+heterodimerization.">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.</a> Molecular Cell. 20 (6), 963-969 (2005).</li><li>Hatzivassiliou, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth.">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.</a> Nature. 464 (7287), 431-435 (2010).</li><li>Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., Rosen, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF.">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.</a> Nature. 464 (7287), 427-430 (2010).</li><li>Kolch, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Meaningful+relationships:+the+regulation+of+the+Ras/RAF/MEK/ERK+pathway+by+protein+interactions.">Meaningful relationships: the regulation of the Ras/RAF/MEK/ERK pathway by protein interactions.</a> Biochemistry Journal. 351, 289-305 (2000).</li><li>Cseh, B., Doma, E., Baccarini, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term="RAF"+neighborhood:+protein-protein+interaction+in+the+Raf/Mek/Erk+pathway.">"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.</a> FEBS Letters. 588 (15), 2398-2406 (2014).</li><li>Garc&#237;a-G&#243;mez, R., Bustelo, X. R., Crespo, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protein-Protein+Interactions:+Emerging+Oncotargets+in+the+RAS-ERK+Pathway.">Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.</a> Trends Cancer. 4 (9), 616-633 (2018).</li><li>Luker, K. E., Smith, M. C., Luker, G. D., Gammon, S. T., Piwnica-Worms, H., Piwnica-Worms, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Kinetics+of+regulated+protein&#8211;protein+interactions+revealed+with+firefly+luciferase+complementation+imaging+in+cells+and+living+animals.">Kinetics of regulated protein&#8211;protein interactions revealed with firefly luciferase complementation imaging in cells and living animals.</a> Proceedings of the National Academy of Sciences of the United States of America. 101 (33), 12288-12293 (2004).</li><li>Chen, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oncogenic+BRAF+deletions+that+function+as+homodimers+and+are+sensitive+to+inhibition+by+RAF+dimer+inhibitor+LY3009120.">Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120.</a> Cancer Discovery. 6 (3), 300-315 (2016).</li><li>Foster, S. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Activation+mechanism+of+oncogenic+deletion+mutations+in+BRAF,+EGFR,+and+HER2.">Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2.</a> Cancer Cell. 29 (4), 477-493 (2016).</li></ol>

In this article, we presented three methods for characterizing disease-related RAF mutants, which include in vitro kinase assay, RAF co-activation assay, and complimentary split luciferase assay. Since RAF kinases have both catalytic activity and allosteric activity, various RAF mutants can activate the downstream signaling through two distinct mechanisms13,14,16,17,<sup class="xref"...

The RAF family kinases are a key component of RAS/RAF/MEK/ERK signaling cascade, which transmit a signal from RAS to activate mitogen-activated protein kinase (MEK)1,2,3,4. This family of kinases plays a crucial role in cell growth, survival and differentiation, and their alterations induce many diseases, notably cancer5,6,7,8. Recently, genomic sequencings have identified many disease-related RAF mutants that exhibit different properties in the signal transmission of RAS/RAF/MEK/ERK cascade9,10,11. A careful characterization of RAF mutants will help us understand the molecular mechanisms of how RAF mutants alter the signal output of RAS/RAF/MEK/ERK cascade, eventually select appropriate approaches for treating various RAF mutant-driven diseases.
The RAF family kinases include three members, CRAF, BRAF, and ARAF, which have similar molecular structures but different abilities to activate downstream signaling1,2,3,4. Among these paralogs, BRAF has the highest activity by virtue of its constitutively phosphorylated NtA (N-terminal acidic) motif12,13,14, while ARAF has the lowest activity arising from its non-canonical APE motif15. This may explain the different mutation frequencies of RAF paralogs in diseases: BRAF&#62;CRAF&#62;ARAF. Moreover, within the same RAF paralog, mutations in different sites may trigger downstream signaling in distinct manners, which adds another layer of complexity to the regulation of RAF family kinases. Recent studies have demonstrated that all RAF kinases have both catalytic and allosteric activities13,14,16,17,18. Constitutively active RAF mutants turn on the downstream signaling directly by phosphorylating MEK, whereas kinase-dead RAF mutants can transactivate their wild-type counterparts through side-to-side dimerization and activate MEK-ERK signaling16,19,20. The dimer affinity/stability is a key parameter that not only determines the allosteric activity of kinase-dead RAF mutants but also affects the catalytic activity of constitutively active RAF mutants15,21,22. The kinase-dead RAF mutants with high dimer affinity/stability can transactivate the endogenous wild-type RAFs directly15, while those with intermediate dimer affinity/stability requires a coordination of active Ras or an elevated level of wild-type RAF molecules to function13,15,20,21,23. Similarly, constitutively active RAF mutants phosphorylate MEK in a dimer-dependent manner, and those with low dimer affinity/stability lose their catalytic activity in vitro upon immunoprecipitation that breaks the weak RAF dimers15,21,22. The dimer affinity/stability also determines the sensitivity of RAF mutants to their inhibitors, and positively correlates to the resistance of RAF inhibitors24. Therefore, to characterize disease-related RAF mutants, it is necessary to measure their catalytic and allosteric activities, and dimer affinity/stability.
In recent years, our laboratory and others have developed various methods to characterize RAF family kinases and their mutants. According to our laboratory and others&#39;&#160;experience, we think that the following three assays have advantages in defining disease-related RAF mutants: (1) the in vitro kinase assay that can be carried out with ease to detect the catalytic activity of constitutively active RAF mutants15; (2) the RAF co-activation assay that is a reliable and convenient method to measure the allosteric activity of kinase-dead RAF mutants13,15,21,22,23,25; (3) the complimentary split luciferase assay that has much higher sensitivity in measuring the relative dimer affinity/stability of RAF mutants in contrast to the traditional co-immunoprecipitation assay, and is able to carry out without advanced equipment in contrast to the quantitative analytic methods such as SPR (Surface Plasmon Resonance) analysis15,22. Combining these three assays, we can understand easily how a disease-related RAF mutant alters the downstream signaling and thereby utilize an appropriate therapeutic strategy to treat the disease caused by this RAF mutation.

<table border="0" cellpadding="0" cellspacing="0" style="width:660px;" width="660">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-phosphoERK1/2</td>
			<td style="width:197px;">Cell Signaling Technologies</td>
			<td style="width:104px;">4370</td>
			<td style="width:164px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-phosphoMEK1/2</td>
			<td style="width:197px;">Cell Signaling Technologies</td>
			<td style="width:104px;">9154</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-ERK1/2</td>
			<td style="width:197px;">AB clonal</td>
			<td style="width:104px;">A0229</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-MEK1/2</td>
			<td style="width:197px;">Cell Signaling Technologies</td>
			<td style="width:104px;">9124</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-FLAG(mouse)</td>
			<td style="width:197px;">Sigma-Aldrich</td>
			<td style="width:104px;">F3165</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-HA</td>
			<td style="width:197px;">Novus Biologicals</td>
			<td style="width:104px;">MAB6875</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-FLAG(Rabbit)</td>
			<td style="width:197px;">Cell Signaling Technologies</td>
			<td style="width:104px;">14793</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-&#946;-actin</td>
			<td style="width:197px;">Sigma-Aldrich</td>
			<td style="width:104px;">A2228</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">anti-FLAG beads(M2)</td>
			<td style="width:197px;">Sigma-Aldrich</td>
			<td style="width:104px;">A4596</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:195px;">HRP-conjugated anti-mouse IgG</td>
			<td style="width:197px;">Jackson Laboratories</td>
			<td style="width:104px;">115-035-003</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:195px;">HRP-conjugated anti-Rabbit IgG</td>
			<td style="width:197px;">Jackson Laboratories</td>
			<td style="width:104px;">111-035-144</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">pcDNA3.1(+)</td>
			<td style="width:197px;">In vitrogen</td>
			<td style="width:104px;">V79020</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:195px;">Gibson Assembly Cloning&#160; Kit</td>
			<td style="width:197px;">New England Biolabs</td>
			<td style="width:104px;">E5510</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">T4 DNA ligase</td>
			<td style="width:197px;">New England Biolabs</td>
			<td style="width:104px;">M0202</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">lipofectamine 2000</td>
			<td style="width:197px;">Invitrogen</td>
			<td align="right" style="width:104px;">11668019</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:195px;">Fugene 6</td>
			<td style="width:197px;">Roche</td>
			<td style="width:104px;">11 814 443 001</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">DMEM w/o phenol red</td>
			<td style="width:197px;">Invitrogen</td>
			<td style="width:104px;">21063-029</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">D-luciferin&#160;</td>
			<td style="width:197px;">GoldBio</td>
			<td style="width:104px;">LUCK-100</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:195px;">6xhis-tagged MEK1 (K97A)</td>
			<td style="width:197px;">&#160;prepared in our previous studies</td>
			<td style="width:104px;">N.A.</td>
			<td>Reference 15.</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">GloMax-Multi Detection System.</td>
			<td style="width:197px;">Promega</td>
			<td style="width:104px;">E7041</td>
			<td></td>
		</tr>
	</tbody>
</table>

characterize disease-related mutants of raf family kinases by using a set of practical and feasible methods

The rapidly accelerated fibrosarcoma (RAF) family kinases play a central role in cell biology and their dysfunction leads to cancers and developmental disorders. A characterization of disease-related RAF mutants will help us select appropriate therapeutic strategies for treating these diseases. Recent studies have shown that RAF family kinases have both catalytic and allosteric activities, which are tightly regulated by dimerization. Here, we constructed a set of practical and feasible methods to determine the catalytic and allosteric activities and the relative dimer affinity/stability of RAF family kinases and their mutants. Firstly, we amended the classical in vitro kinase assay by reducing the detergent concentration in buffers, utilizing a gentle quick wash procedure, and employing a glutathione S-transferase (GST) fusion to prevent RAF dimers from dissociating during purification. This enables us to measure the catalytic activity of constitutively active RAF mutants appropriately. Secondly, we developed a novel RAF co-activation assay to evaluate the allosteric activity of kinase-dead RAF mutants by using N-terminal truncated RAF proteins, eliminating the requirement of active Ras in current protocols and thereby achieving a higher sensitivity. Lastly, we generated a unique complementary split luciferase assay to quantitatively measure the relative dimer affinity/stability of various RAF mutants, which is more reliable and sensitive compared to the traditional co-immunoprecipitation assay. In summary, these methods have the following advantages: (1) user-friendly; (2) able to carry out effectively without advanced equipment; (3) cost-effective; (4) highly sensitive and reproducible.

The RAF family kinases have both catalytic and allosteric activities, which enable their disease-related mutants to turn on the downstream signaling through different mechanisms13,14,16,17,18. The constitutively active RAF mutants directly phosphorylate their substrates, while the kinase-dead RAF mutants fulfill their function through transactivating wild-type...

Watch this Scientific Journal Video about Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods at JoVE.com

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

In this article, we presented a set of practical and feasible methods for characterizing disease-related mutants of RAF family kinases, which include in vitro kinase assay, RAF co-activation assay, and complementary split luciferase assay.

The rapidly accelerated fibrosarcoma (RAF) family kinases play a central role in cell biology and their dysfunction leads to cancers and developmental ...

Research

JoVE Journal

Cancer Research

A Mouse Model of Fatigue Induced by Peripheral Irradiation

Cancer-related fatigue (CRF) is a distressing and costly condition that often affects patients receiving cancer treatments, including radiation therapy. ...

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

The pulmonary metastasis assay (PuMA) is an ex vivo lung explant and closed cell culture system that permits researchers to study the biology of lung ...

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

For decades, small animal radiation research was mostly performed using fairly crude experimental setups applying simple single-beam techniques without ...

Imaging Approaches to Assessments of Toxicological Oxidative Stress Using Genetically-encoded Fluorogenic Sensors

While oxidative stress is a commonly cited toxicological mechanism, conventional methods to study it suffer from a number of shortcomings, including ...

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, ...

Detection of Protease Activity by Fluorescent Peptide Zymography

The purpose of this method is to measure the proteolytic activity of complex biological samples. The samples are separated by molecular weight using ...

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Neuroendocrine tumors are a rare form of cancer that arise from neuroendocrine cells and can be present at almost any location throughout the body. ...

In Vitro Assay to Study Tumor-macrophage Interaction

Tumor associated macrophages (TAMs) account for a large percentage of cells in the tumor mass for different types of cancers. Glioblastoma (GBM), a ...

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Formation of the eIF4F complex has been shown to be the key downstream node for the convergence of signalling pathways that often undergo&#160;oncogenic ...

Using Computer-based Image Analysis to Improve Quantification of Lung Metastasis in the 4T1 Breast Cancer Model

Breast cancer is a devastating malignancy, accounting for 40,000 female deaths and 30% of new female cancer diagnoses in the United States in 2019 alone. ...